Pfizer Inc. (PFE) Financials
Key financial figures for Pfizer Inc. (Q3 2026).
Pfizer raised full-year 2026 guidance to $62.0-64.0 billion in revenue and $2.95-3.05 adjusted diluted EPS after Q3 revenue of $16.58 billion was flat year over year. Q3 2026 revenue was $16,583 million versus $16,654 million a year earlier (flat as printed); excluding Comirnaty and Paxlovid, revenue grew 7% operationally, and launched and acquired products grew 32% operationally. The release does not state an analyst estimate. Reported diluted EPS was $0.56 versus $0.62 a year earlier; adjusted diluted EPS was $0.87, unchanged from $0.87 in Q3 2025. Reported net income was $3,242 million versus $3,541 million. On the outlook: Raised full-year 2026 revenue guidance to $62.0 to $64.0 billion (previously $60.5 to $62.5 billion) and raised and narrowed adjusted diluted EPS guidance to $2.95 to $3.05 (previously $2.80 to $3.00), including about $0.10 of unfavorable impact from the one-time $650 million Innovent acquired IPR&D charge; adjusted R&D expenses $10.8 to $11.8 billion (previously $10.5 to $11.5 billion), adjusted SI&A expenses $12.5 to $13.5 billion, adjusted tax rate approximately 15.0%. Figures are for Q3 2026, as Pfizer Inc. reported them.
- Revenue
- $16.6B
- Net Income
- $3.2B
- EPS
- $0.57
- Total Assets
- $204.5B
- Operating Cash Flow
- $5.4B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $16.6B | $3.2B | $0.56 | $4.8B | |
| Q2 FY2026 | $15.0B | -$248M | -$0.04 | $302M | |
| Q1 FY2026 | $14.4B | $2.7B | $0.47 | $2.2B | |
| Q4 FY2025 | $17.6B | -$1.6B | -$0.29 | $4.5B | |
| Q3 FY2025 | $16.7B | $3.5B | $0.62 | $4.0B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $62.6B | $7.8B | $1.36 | $9.1B | |
| FY2024 | $63.6B | $8.0B | $1.41 | $9.8B | |
| FY2023 | $59.6B | $2.1B | $0.37 | $4.8B |
Frequently asked questions
What was Pfizer Inc.'s revenue last quarter?
Pfizer Inc. reported revenue of $16.58 billion for Q3 FY2026, down 0.4% from the same period a year earlier.
Is Pfizer Inc. profitable?
Yes. Pfizer Inc. reported net income of $3.24 billion for Q3 FY2026, a net margin of 19.55% on revenue.
How much free cash flow did Pfizer Inc. generate?
Pfizer Inc. generated free cash flow of $4.80 billion in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Pfizer Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.